Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Am J Kidney Dis. 2018 Apr 10;72(3):337–348. doi: 10.1053/j.ajkd.2018.02.350

Figure 3. Association between carvedilol versus metoprolol initiation and 1-year mortality: intent-to-treat analysis.

Figure 3.

An intent-to-treat design was employed in all analyses. Cox proportional hazards models were used to estimate the association between carvedilol (versus metoprolol) initiation and 1-year all-cause mortality. Fine and Gray proportional subdistribution hazards models were used to estimate the association between carvedilol (versus metoprolol) initiation and 1-year cardiovascular mortality. In cardiovascular mortality analyses, non-cardiovascular death was treated as a competing risk. Inverse probability of treatment weighting was used in adjusted analyses to control for all the baseline covariates listed in Table 1.

Abbreviations: CI, confidence interval; HR, hazard ratio; ref., referent